Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study

BACKGROUND: Ketamine at subanaesthetic dosages (≤0.5mg/kg) exhibits rapid onset (over hours to days) antidepressant effects against major depressive disorder in people who are otherwise well. However, its safety, tolerability and efficacy are not known for major depressive disorder in people with ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Wei, Sheehan, Caitlin, Chye, Richard, Chang, Sungwon, Bayes, Adam, Loo, Colleen, Draper, Brian, Agar, Meera R., Currow, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645343/
https://www.ncbi.nlm.nih.gov/pubmed/37963146
http://dx.doi.org/10.1371/journal.pone.0290876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645343/
https://www.ncbi.nlm.nih.gov/pubmed/37963146
http://dx.doi.org/10.1371/journal.pone.0290876

Ejemplares similares